Loading patent…
AssigneeHessian Labs, Inc.
InventorsGiannoula Lakka KLEMENT, Abdo ABOU-SLAYBI, Darrol G. ROBERTS
Estimating the term…
Eleven percent of all men will develop prostate cancer (PC). In the US, 3 million men are living with the disease, 192,000 new cases are expected, and 33,000 men will die from the illness this year. PC is the second leading cause of cancer (CA) deaths in men worldwide, the diagnosis of PC relies on a combination of tests and procedures, including the digital rectal exam (DRE), magnetic resonance imaging (MRI), ultrasound, and multiple tissue biopsies, each with escalating costs and risks. In 2018, the cost of PC care in the US was $15.3 billion dollars, of which $5.7 billion was spent on diagnosis and $8.3 billion on management. There is a critical need for an early, accurate, reliable and cancer specific diagnostic for PC. The technology as described herein relates to compositions and methods for diagnosing and staging of cancer in a subject.
A method of diagnosing cancer in a subject, the method comprising:
A device for the diagnosis of cancer, the device comprising reagents sufficient to detect, in a sample of platelets or platelet proteins from a subject, the presence and/or amount of a set of polypeptides comprising subsets of polypeptides that are representative of functions in cancer development including each of malignant cell transformation, invasion, angiogenesis and metastasis.
A kit for the detection, in a sample of platelets or platelet proteins from a subject, of the presence and/or amount of a set of polypeptides comprising subsets of polypeptides that are representative of functions in cancer development including each of transformation, invasion, angiogenesis and metastasis,
A kit for the staging of cancer, the kit comprising reagents necessary for detecting in a platelet sample the presence and/or amount of sets of polypeptides in functional cancer development categories including each of malignant cell transformation, invasion, angiogenesis and metastasis.
A solid support comprising reagents sufficient to detect, in a sample of platelet proteins from a subject, polypeptides in each of a set of functional cancer development categories including malignant cell transformation, invasion, angiogenesis and metastasis.
A method of monitoring cancer treatment for efficacy in a subject, the method comprising:
Dependencies are inferred from the claim text.